Limits...
Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells.

Hosonaga M, Arima Y, Sugihara E, Kohno N, Saya H - Cancer Sci. (2014)

Bottom Line: However, resistance to HER2-targeted therapy remains a major clinical problem.HER2-positive breast tumors are predominantly positive for CD24, suggesting that the expression of the two molecules is related.Flow cytometry thus revealed that the percentage of CD24-positive cells was markedly higher in the HER2-positive fraction than in the HER2-negative fraction.

View Article: PubMed Central - PubMed

Affiliation: Division of Gene Regulation, Institute for Advanced Medical Research, School of Medicine, Keio University, Tokyo, Japan; Department of Breast Oncology, Tokyo Medical University, Tokyo, Japan.

Show MeSH

Related in: MedlinePlus

Effect of overexpression of human epidermal growth factor receptor 2 (HER2) on tumor growth in an orthotopic xenograft model. (a) Bioluminescence imaging of nude mice injected with 231-Luc, HER2-60 or HER2-90 cells in a mammary fat pad at 4 weeks after cell injection. (b) Volume of orthotopic tumors determined at the indicated times after cell injection as in (a). Data are means ± SD for 8 to 10 mice per group. NS, not significant for comparison of 231-Luc cells with HER2-60 or HER2-90 cells (Student's t-test). (c) H&E staining and immunohistochemical analysis of HER2 expression in formalin-fixed, paraffin-embedded sections of orthotopic tumors formed at 3 to 4 weeks after cell injection. Scale bars, 200 μm.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317915&req=5

fig03: Effect of overexpression of human epidermal growth factor receptor 2 (HER2) on tumor growth in an orthotopic xenograft model. (a) Bioluminescence imaging of nude mice injected with 231-Luc, HER2-60 or HER2-90 cells in a mammary fat pad at 4 weeks after cell injection. (b) Volume of orthotopic tumors determined at the indicated times after cell injection as in (a). Data are means ± SD for 8 to 10 mice per group. NS, not significant for comparison of 231-Luc cells with HER2-60 or HER2-90 cells (Student's t-test). (c) H&E staining and immunohistochemical analysis of HER2 expression in formalin-fixed, paraffin-embedded sections of orthotopic tumors formed at 3 to 4 weeks after cell injection. Scale bars, 200 μm.

Mentions: We injected 231-Luc, HER2-60 or HER2-90 cells (2 × 105) into a mammary fat pad of female nude mice in order to examine tumor growth in an orthotopic xenograft model. Tumors formed by HER2-60 or HER2-90 cells tended to be larger than those formed by 231-Luc cells, although the differences were not statistically significant (Fig. 3a,b). Immunohistochemical analysis of formalin-fixed tumor tissue revealed the proportionate overexpression of HER2 in tumors formed from HER2-60 or HER2-90 cells, whereas HER2 immunoreactivity was not detected in 231-Luc tumors (Fig. 3c).


Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells.

Hosonaga M, Arima Y, Sugihara E, Kohno N, Saya H - Cancer Sci. (2014)

Effect of overexpression of human epidermal growth factor receptor 2 (HER2) on tumor growth in an orthotopic xenograft model. (a) Bioluminescence imaging of nude mice injected with 231-Luc, HER2-60 or HER2-90 cells in a mammary fat pad at 4 weeks after cell injection. (b) Volume of orthotopic tumors determined at the indicated times after cell injection as in (a). Data are means ± SD for 8 to 10 mice per group. NS, not significant for comparison of 231-Luc cells with HER2-60 or HER2-90 cells (Student's t-test). (c) H&E staining and immunohistochemical analysis of HER2 expression in formalin-fixed, paraffin-embedded sections of orthotopic tumors formed at 3 to 4 weeks after cell injection. Scale bars, 200 μm.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317915&req=5

fig03: Effect of overexpression of human epidermal growth factor receptor 2 (HER2) on tumor growth in an orthotopic xenograft model. (a) Bioluminescence imaging of nude mice injected with 231-Luc, HER2-60 or HER2-90 cells in a mammary fat pad at 4 weeks after cell injection. (b) Volume of orthotopic tumors determined at the indicated times after cell injection as in (a). Data are means ± SD for 8 to 10 mice per group. NS, not significant for comparison of 231-Luc cells with HER2-60 or HER2-90 cells (Student's t-test). (c) H&E staining and immunohistochemical analysis of HER2 expression in formalin-fixed, paraffin-embedded sections of orthotopic tumors formed at 3 to 4 weeks after cell injection. Scale bars, 200 μm.
Mentions: We injected 231-Luc, HER2-60 or HER2-90 cells (2 × 105) into a mammary fat pad of female nude mice in order to examine tumor growth in an orthotopic xenograft model. Tumors formed by HER2-60 or HER2-90 cells tended to be larger than those formed by 231-Luc cells, although the differences were not statistically significant (Fig. 3a,b). Immunohistochemical analysis of formalin-fixed tumor tissue revealed the proportionate overexpression of HER2 in tumors formed from HER2-60 or HER2-90 cells, whereas HER2 immunoreactivity was not detected in 231-Luc tumors (Fig. 3c).

Bottom Line: However, resistance to HER2-targeted therapy remains a major clinical problem.HER2-positive breast tumors are predominantly positive for CD24, suggesting that the expression of the two molecules is related.Flow cytometry thus revealed that the percentage of CD24-positive cells was markedly higher in the HER2-positive fraction than in the HER2-negative fraction.

View Article: PubMed Central - PubMed

Affiliation: Division of Gene Regulation, Institute for Advanced Medical Research, School of Medicine, Keio University, Tokyo, Japan; Department of Breast Oncology, Tokyo Medical University, Tokyo, Japan.

Show MeSH
Related in: MedlinePlus